title: Antiphospholipid and Antinuclear Antibodies in Young Patients after Myocardial Revascularization Procedures.
abstract: BACKGROUND
  The role of autoimmune factors in the etiology of coronary artery disease (CAD) was suggested in numerous studies but has not been definitively determined.
  
  
  OBJECTIVE
  To assess the possible influence of antiphospholipid and antinuclear antibodies on atherosclerosis development in young patients after myocardial revascularization procedures.
  
  
  METHODS
  The study group included 39 patients younger than 45 years with CAD who underwent myocardial revascularization. Serum levels of antiphospholipid (aPL), antinuclear (ANA) and antineutrophil cytoplasmatic (ANCA) antibodies were tested within 1 month after the procedure.
  
  
  RESULTS
  All three types of aPL were significantly higher in CAD patients when compared to healthy controls: anti-β2-glycoprotein I (aβ2GPI), both immunoglobulin (Ig)G and IgM classes (median 4.10 SGU, range 3.45-21.63 vs. 0.76, 0.12-6.01, P < 0.001, and 2.82 SGU, 1.44-11.70 vs. 1.08, 0.44-3.64, P < 0.001, respectively); anticardiolipin antibodies (aCL) both IgG and IgM classes (3.13 GPL, 1.32-14.03 vs. 2.42, 0.96-18.45, P = 0.0037, and 6.94 MPL, 1.90-26.40 vs. 4.32, 1.9-28.73, P < 0.008, respectively); and lupus anticoagulant (LA) (27.7% vs. 0%, P = 0.005). ANA were elevated in one patient and ANCA in 23 (60%). The levels of aPL did not correlate with the presence of a clot in a coronary vessel detected during angiography or with exacerbation of coronary artery atherosclerosis.
  
  
  CONCLUSIONS
  In young patients with CAD who underwent myocardial revascularization the levels of aPL were significantly higher than in young healthy subjects. Thus, besides the classic risk factors for CAD, autoimmunity may play an important role in atherosclerotic plaque formation and progression.
authors.forename: Adam
authors.initials: A
authors.lastname: Mazurek
authors.forename: Teresa
authors.initials: T
authors.lastname: Iwaniec
authors.forename: Maria
authors.initials: M
authors.lastname: Olszowska
authors.forename: Carlo
authors.initials: C
authors.lastname: Perricone
authors.forename: Barbara
authors.initials: B
authors.lastname: Widlinska
authors.forename: Piotr
authors.initials: P
authors.lastname: Podolec
authors.forename: Jacek
authors.initials: J
authors.lastname: Musial
authors.forename: Wojciech
authors.initials: W
authors.lastname: Plazak
mesh_terms: D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D000974:Antibodies, Antinuclear / Q000097:blood*; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D050197:Atherosclerosis / Q000276:immunology*; D015551:Autoimmunity; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000276:immunology* / Q000601:surgery; D003331:Coronary Vessels / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D009204:Myocardial Revascularization / Q000379:methods*; D011184:Postoperative Period; D012307:Risk Factors; D013223:Statistics as Topic
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D000974:Antibodies, Antinuclear; D017152:Antibodies, Antiphospholipid